GlaxoSmithKline (NYSE: GSK) and partner Janssen Biologics advance a rheumatoid arthritis drug to two trials that targets moderate to severe cases.
Janssen is based in Ireland.
The two companies have been working together since 2011 on the antibody-based treatment called sirukumab.
“The start of the Phase III programme in rheumatoid arthritis is an important milestone in our collaboration with Janssen Biologics.” said Paul-Peter Tak, senior vice president for GSK Immuno-inflammation. “It shows progress in the challenging area of autoimmune diseases and our focus of bringing a promising new therapeutic option to patients living with this debilitating disease.”
GSK operates its U.S. headquarters in Research Triangle Park, N.C.
[GSK ARCHIVE: Check out a decade of GSK stories as reported in WRAL Tech Wire.]